F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians, vol.68, issue.6, pp.394-424, 2018.

F. Mégraud, E. Bessède, and C. Varon, Helicobacter pylori infection and gastric carcinoma, Clinical Microbiology and Infection, vol.21, issue.11, pp.984-990, 2015.

, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, vol.513, issue.7517, pp.202-209, 2014.

K. Wang, S. T. Yuen, J. Xu, S. P. Lee, H. H. Yan et al., Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer, Nature Genetics, vol.46, issue.6, pp.573-582, 2014.

R. Cristescu, J. Lee, M. Nebozhyn, K. M. Kim, J. C. Ting et al., Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nature Medicine, vol.21, issue.5, pp.449-456, 2015.

Z. Lei, I. B. Tan, K. Das, N. Deng, H. Zouridis et al., Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil, Gastroenterology, vol.145, issue.3, pp.554-565, 2013.

J. G. Association, Japanese gastric cancer treatment guidelines 2014 (ver. 4), Gastric Cancer, vol.20, issue.1, pp.1-19, 2016.

E. C. Smyth, M. Verheij, W. Allum, D. Cunningham, A. Cervantes et al., Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.27, pp.v38-v49, 2016.

P. Van-hagen, M. C. Hulshof, J. J. Van-lanschot, E. W. Steyerberg, M. I. Henegouwen et al., Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer, New England Journal of Medicine, vol.366, issue.22, pp.2074-2084, 2012.

E. Carrasco-garcia, M. García-puga, S. Arevalo, and A. Matheu, Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer, Therapeutic Advances in Medical Oncology, vol.10, p.175883591879462, 2018.

H. H. Hartgrink, E. P. Jansen, N. C. Van-grieken, and C. J. Van-de-velde, Gastric cancer, The Lancet, vol.374, issue.9688, pp.477-490, 2009.

K. D. Courtney, R. B. Corcoran, and J. A. Engelman, The PI3K Pathway As Drug Target in Human Cancer, Journal of Clinical Oncology, vol.28, issue.6, pp.1075-1083, 2010.

B. D. Manning and A. Toker, AKT/PKB Signaling: Navigating the Network, Cell, vol.169, issue.3, pp.381-405, 2017.

J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero, Development of PI3K inhibitors: lessons learned from early clinical trials, Nature Reviews Clinical Oncology, vol.10, issue.3, pp.143-153, 2013.

S. Z. Millis, S. Ikeda, S. Reddy, Z. Gatalica, and R. Kurzrock, Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors, JAMA Oncology, vol.2, issue.12, p.1565, 2016.

M. H. Kang, J. S. Kim, J. E. Seo, S. C. Oh, and Y. A. Yoo, BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, Experimental Cell Research, vol.316, issue.1, pp.24-37, 2010.

M. Zang, B. Zhang, Y. Zhang, J. Li, L. Su et al., CEACAM6 Promotes Gastric Cancer Invasion and Metastasis by Inducing Epithelial-Mesenchymal Transition via PI3K/AKT Signaling Pathway, PLoS ONE, vol.9, issue.11, p.e112908, 2014.

J. Ye, J. Huang, J. Xu, Q. Huang, J. Wang et al., ERp29 controls invasion and metastasis of gastric carcinoma by inhibition of epithelial-mesenchymal transition via PI3K/Aktsignaling pathway, BMC Cancer, vol.17, issue.1, 2017.

C. Sun, Y. Tao, Y. Gao, Y. Xia, Y. Liu et al., F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT, Biomedicine & Pharmacotherapy, vol.98, pp.416-423, 2018.

S. Wei, L. Wang, L. Zhang, B. Li, Z. Li et al., ZNF143 enhances metastasis of gastric cancer by promoting the process of EMT through PI3K/AKT signaling pathway, Tumor Biology, vol.37, issue.9, pp.12813-12821, 2016.

W. Lu, Y. Zuo, Z. Xu, and M. Zhang, MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer, World Journal of Gastroenterology, vol.21, issue.15, pp.4564-4573, 2015.

P. H. Nguyen, J. Giraud, L. Chambonnier, P. Dubus, L. Wittkop et al., Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma, Clinical Cancer Research, vol.23, issue.6, pp.1586-1597, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-03004874

E. Bessède, C. Staedel, L. A. Acuña-amador, P. H. Nguyen, L. Chambonnier et al., Helicobacter pylori generates cells with cancer stem cell properties via epithelial?mesenchymal transition-like changes, Oncogene, vol.33, issue.32, pp.4123-4131, 2013.

E. Bessède, P. Dubus, F. Mégraud, and C. Varon, Helicobacter pylori infection and stem cells at the origin of gastric cancer, Oncogene, vol.34, issue.20, pp.2547-2555, 2014.

P. H. Nguyen, J. Giraud, C. Staedel, L. Chambonnier, P. Dubus et al., All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth, Oncogene, vol.35, issue.43, pp.5619-5628, 2016.

S. Courtois, R. V. Durán, J. Giraud, E. Sifré, J. Izotte et al., Metformin targets gastric cancer stem cells, European Journal of Cancer, vol.84, pp.193-201, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-03004867

M. Y. Kim, T. Oskarsson, S. Acharyya, D. X. Nguyen, N. F. Zhang et al., Tumor Self-Seeding by Circulating Cancer Cells, Cell, vol.139, issue.7, pp.1315-1326, 2009.

S. A. Mani, W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan et al., The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells, Cell, vol.133, issue.4, pp.704-715, 2008.

L. Yang, G. Yang, Y. Ding, Y. Huang, S. Liu et al., Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency, Oncology Reports, vol.40, pp.479-487, 2018.

E. Park, J. Park, S. W. Han, S. A. Im, T. Y. Kim et al., NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations, International Journal of Oncology, vol.40, issue.4, pp.1259-1266, 2011.

A. Mueller, E. Bachmann, M. Linnig, K. Khillimberger, C. C. Schimanski et al., Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines, Cancer Chemotherapy and Pharmacology, vol.69, issue.6, pp.1601-1615, 2012.

R. M. Hoffman, Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts, Nature Reviews Cancer, vol.15, issue.8, pp.451-452, 2015.

T. Furukawa, T. Kubota, M. Watanabe, M. Kitajima, and R. M. Hoffman, Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: Correlation of metastatic sites in mouse and individual patient donors, International Journal of Cancer, vol.53, issue.4, pp.608-612, 1993.

S. Bhargava, B. Hotz, H. J. Buhr, and H. G. Hotz, An orthotopic nude mouse model for preclinical research of gastric cardia cancer, International Journal of Colorectal Disease, vol.24, issue.1, pp.31-39, 2008.

R. A. Busuttil, D. S. Liu, N. Di-costanzo, J. Schröder, C. Mitchell et al., An orthotopic mouse model of gastric cancer invasion and metastasis, Scientific Reports, vol.8, issue.1, 2018.

H. Hu, J. Liu, L. Yao, J. Yin, N. Su et al., Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model, Oncol. Rep, vol.27, pp.1937-1943, 2012.

H. Y. Feng, Y. Zhang, H. J. Liu, X. Dong, S. C. Yang et al., Characterization of an orthotopic gastric cancer mouse model with lymph node and organ metastases using bioluminescence imaging, Oncology Letters, vol.16, pp.5179-5185, 2018.

T. Brabletz, A. Jung, S. Spaderna, F. Hlubek, and T. Kirchner, Migrating cancer stem cells ? an integrated concept of malignant tumour progression, Nature Reviews Cancer, vol.5, issue.9, pp.744-749, 2005.

A. P. Morel, M. Lièvre, C. Thomas, G. Hinkal, S. Ansieau et al., Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition, PLoS ONE, vol.3, issue.8, p.e2888, 2008.

E. Bessède, S. Molina, L. A. Amador, P. Dubus, C. Staedel et al., Deletion of IQGAP1 promotes Helicobacter pylori-induced gastric dysplasia in mice and acquisition of cancer stem cell properties in vitro, Oncotarget, vol.7, issue.49, pp.80688-80699, 2016.

S. Takaishi, T. Okumura, S. Tu, S. S. Wang, W. Shibata et al., Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44, Stem Cells, vol.27, issue.5, pp.1006-1020, 2009.

M. Li, B. Zhang, Z. Zhang, X. Liu, X. Qi et al., Stem Cell-Like Circulating Tumor Cells Indicate Poor Prognosis in Gastric Cancer, BioMed Research International, vol.2014, pp.1-7, 2014.

K. Toyoshima, A. Hayashi, M. Kashiwagi, N. Hayashi, M. Iwatsuki et al., Analysis of circulating tumor cells derived from advanced gastric cancer, International Journal of Cancer, vol.137, issue.4, pp.991-998, 2015.

P. L. Bedard, J. Tabernero, F. Janku, Z. A. Wainberg, L. Paz-ares et al., A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors, Clinical Cancer Research, vol.21, issue.4, pp.730-738, 2014.

A. J. Mcree, H. K. Sanoff, C. Carlson, A. Ivanova, and B. H. O?neil, A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors, Investigational New Drugs, vol.33, issue.6, pp.1225-1231, 2015.

J. C. Bendell, J. Rodon, H. A. Burris, M. De-jonge, J. Verweij et al., Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.30, issue.3, pp.282-290, 2012.

B. K. Ragon, H. Kantarjian, E. Jabbour, F. Ravandi, J. Cortes et al., Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias, American Journal of Hematology, vol.92, issue.1, pp.7-11, 2016.

U. A. Matulonis, G. M. Wulf, W. T. Barry, M. Birrer, S. N. Westin et al., Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer, Annals of Oncology, vol.28, issue.3, pp.512-518, 2017.

P. E. Heudel, M. Fabbro, C. Roemer-becuwe, M. C. Kaminsky, A. Arnaud et al., Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I?type II study from the GINECO group, British Journal of Cancer, vol.116, issue.3, pp.303-309, 2017.

A. J. Armstrong, S. Halabi, P. Healy, J. J. Alumkal, C. Winters et al., Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer, European Journal of Cancer, vol.81, pp.228-236, 2017.

D. Soulières, S. Faivre, R. Mesía, É. Remenár, S. H. Li et al., Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial, The Lancet Oncology, vol.18, issue.3, pp.323-335, 2017.

J. Baselga, S. A. Im, H. Iwata, J. Cortés, M. De-laurentiis et al., Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet Oncology, vol.18, issue.7, pp.904-916, 2017.

I. Kobayashi, S. Semba, Y. Matsuda, Y. Kuroda, and H. Yokozaki, Significance of Akt Phosphorylation on Tumor Growth and Vascular Endothelial Growth Factor Expression in Human Gastric Carcinoma, Pathobiology, vol.73, issue.1, pp.8-17, 2006.

, Figure 2?figure supplement 1. Representative images used in the experiment, sampled from http://commons.wikimedia.org/wiki/Main_Page under the Creative Commons Attribution 4.0 International Public License https://creativecommons.org/licenses/by/4.0/., © 2019 by the authors. Licensee MDPI